JBCHEPHARM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | JBCHEPHARM | Market Cap | 35,350 Cr. | Current Price | 2,200 ₹ | High / Low | 2,225 ₹ |
| Stock P/E | 50.9 | Book Value | 251 ₹ | Dividend Yield | 0.71 % | ROCE | 25.2 % |
| ROE | 18.7 % | Face Value | 1.00 ₹ | DMA 50 | 2,069 ₹ | DMA 200 | 1,910 ₹ |
| Chg in FII Hold | 1.45 % | Chg in DII Hold | -1.97 % | PAT Qtr | 116 Cr. | PAT Prev Qtr | 179 Cr. |
| RSI | 63.6 | MACD | 37.5 | Volume | 2,08,571 | Avg Vol 1Wk | 2,87,499 |
| Low price | 1,603 ₹ | High price | 2,225 ₹ | PEG Ratio | 2.35 | Debt to equity | 0.00 |
| 52w Index | 96.0 % | Qtr Profit Var | -22.6 % | EPS | 42.0 ₹ | Industry PE | 30.5 |
📊 Core Financials: JB Chemicals & Pharmaceuticals (JBCHEPHARM) shows moderate fundamentals. ROCE at 25.2% and ROE at 18.7% reflect decent capital efficiency. Debt-to-equity ratio of 0.00 highlights a debt-free balance sheet. Quarterly PAT of ₹116 Cr. declined from ₹179 Cr., showing earnings pressure. EPS of ₹42.0 supports profitability but growth momentum is slowing.
💰 Valuation Indicators: Current P/E of 50.9 is well above the industry average of 30.5, suggesting overvaluation. P/B ratio of ~8.8 (2200/251) reflects premium pricing. PEG ratio of 2.35 indicates growth is expensive. Dividend yield of 0.71% provides modest income return. Intrinsic value appears lower than current price, requiring cautious entry.
🏢 Business Model & Competitive Advantage: JB Chemicals operates in pharmaceuticals with a diversified portfolio across formulations and APIs. Its competitive advantage lies in strong brand presence and debt-free operations. However, profitability growth is inconsistent, and valuations are stretched compared to peers.
📈 Entry Zone: RSI at 63.6 suggests overbought conditions, while MACD positive indicates bullish momentum. Current price of ₹2,200 is near its 52-week high (~₹2,225). Entry between ₹2,000–₹2,100 may be favorable for long-term investors seeking stability.
⏳ Long-Term Holding Guidance: While JB Chemicals benefits from industry demand and debt-free status, high valuation and declining quarterly profits make it suitable only for cautious long-term investors. Accumulation near lower support levels is recommended.
Positive
- 🌟 Debt-free balance sheet (Debt-to-equity 0.00)
- 🌟 Strong ROCE (25.2%) and ROE (18.7%)
- 🌟 Increase in FII holding (+1.45%)
- 🌟 Dividend yield of 0.71% adds income stability
Limitation
- ⚠️ High P/E (50.9) compared to industry average (30.5)
- ⚠️ PEG ratio of 2.35 indicates expensive growth
- ⚠️ Decline in quarterly PAT (₹179 Cr. → ₹116 Cr.)
- ⚠️ RSI at 63.6 suggests overbought conditions
Company Negative News
- 📉 Decline in quarterly profits (-22.6%)
- 📉 Reduction in DII holding (-1.97%)
Company Positive News
- 📈 Increase in FII holding (+1.45%)
- 📈 Strong 52-week performance (+96%)
Industry
- 🌐 Pharmaceutical industry enjoys strong demand globally
- 🌐 Industry P/E at 30.5 reflects growth premium
- 🌐 Competition from peers with stronger growth metrics
Conclusion
✅ JB Chemicals shows decent fundamentals and a debt-free balance sheet but is currently overvalued with declining quarterly profits. Entry between ₹2,000–₹2,100 is favorable for cautious long-term investors. While industry demand supports resilience, valuations remain stretched, requiring careful accumulation.
Would you like me to also compare JB Chemicals with peers like Sun Pharma, Cipla, or Dr. Reddy’s to highlight relative positioning in the pharma sector?